Leukocyte Traffic Blockade as a Therapeutic Strategy in Inflammatory Bowel Disease

Management of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, is generally cumbersome for patients and is a massive health-economic burden. In recent years, the immunomodulating effects of vitamin D have gained a huge interest in its possible pathogenic influence on the pathophysiology of IBD. Vitamin D deficiency is frequent among patients with IBD. Several clinical studies have pointed to a critical role for vitamin D in ameliorating disease outcomes. Although causation versus correlation unfortunately remains an overwhelming issue in the illusive chicken versus egg debate regarding vitamin D and IBD, here we summarise the latest knowledge of the immunological effects of vitamin D in IBD and recommend from available evidence that physicians regularly monitor serum 25(OH)D levels in patients with IBD. Moreover, we propose an algorithm for optimising vitamin D status in patients with IBD in clinical practice. Awaiting well-powered controlled clinical trials, we consider vitamin D supplementation to be an affordable and widely accessible therapeutic strategy to ameliorate IBD clinical outcomes.

Download Full-text

Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease – an update

Expert Review of Clinical Immunology ◽

10.1586/eci.13.11 ◽

2013 ◽

Vol 9 (4) ◽

pp. 301-306 ◽

Cited By ~ 6

Author(s):

Monica Cesarini ◽

Gionata Fiorino

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Traffic Control ◽

Therapeutic Strategy ◽

Inflammatory Bowel ◽

Novel Therapeutic

Download Full-text

JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease

Current Drug Metabolism ◽

10.2174/1389200221666200310111409 ◽

2020 ◽

Vol 21 (4) ◽

pp. 247-255 ◽

Cited By ~ 1

Author(s):

Fabio Salvatore Macaluso ◽

Iago Rodríguez-Lago

Keyword(s):

Ulcerative Colitis ◽

Inflammatory Bowel Disease ◽

Mechanism Of Action ◽

Bowel Disease ◽

Therapeutic Strategy ◽

Kinase Inhibitors ◽

Janus Kinase ◽

Efficacy And Safety ◽

Janus Kinase Inhibitors ◽

Inflammatory Bowel

Background: Inflammatory bowel disease, including both Crohn’s disease and ulcerative colitis, are two chronic and progressive disorders affecting the gastrointestinal tract. Research on the molecular mechanisms of both diseases has led to the introduction of targeted therapies which are able to selectively block the key inflammatory mediators. Methods: Here, we discuss the current evidence about the mechanism of action with an up to date review of the efficacy and safety of Janus kinase inhibitors in inflammatory bowel disease. Results: Multiple small molecule drugs have been evaluated for their use in both ulcerative colitis and Crohn’s disease. Janus kinase inhibitors represent the most important family of these drugs, as their particular mechanism of action enables a simultaneous and effective blockade of multiple cytokines involved in the pathogenesis of the disease. Conclusion: Janus kinase inhibitors represent a promising therapeutic strategy, especially in ulcerative colitis. More data are still necessary regarding its efficacy and safety in clinical practice.

Download Full-text